FiltersReset Filters

With box warnings

Without box warnings

Branded

Generic

6 results

gamifant
(emapalumab-lzsg)
Swedish Orphan Biovitrum AB (publ)
Usage: GAMIFANT is indicated for treating adults and pediatric patients with primary hemophagocytic lymphohistiocytosis (HLH) who have refractory, recurrent, or progressive disease or cannot tolerate conventional HLH therapy.
kepivance
(palifermin)
Swedish Orphan Biovitrum AB (publ)
Usage: Kepivance is indicated to reduce the incidence and duration of severe oral mucositis in patients with hematologic malignancies undergoing myelotoxic therapy with autologous stem cell support. It serves as supportive care for preparative regimens likely to cause ≥ WHO Grade 3 mucositis.
kineret
(anakinra)
Swedish Orphan Biovitrum AB (publ)
Usage: KINERET is indicated for reducing signs and symptoms and slowing structural damage in moderately to severely active rheumatoid arthritis in adults who have failed previous DMARDs. It is also used to treat Neonatal-Onset Multisystem Inflammatory Disease and Deficiency of Interleukin-1 Receptor Antagonist.
orfadin
(Nitisinone)
SWEDISH ORPHAN BIOVITRUM AB (PUBL)
Usage: ORFADIN® is indicated for treating adult and pediatric patients with hereditary tyrosinemia type 1 (HT-1), alongside dietary restriction of tyrosine and phenylalanine.
orfadin
(nitisinone)
Swedish Orphan Biovitrum AB (publ)
Usage: ORFADIN® is indicated for treating adult and pediatric patients with hereditary tyrosinemia type 1 (HT-1), and it should be used alongside a diet that restricts tyrosine and phenylalanine intake.
synagis
(palivizumab)
Swedish Orphan Biovitrum AB (publ)
Usage: Synagis is indicated for preventing serious lower respiratory tract disease caused by RSV in pediatric patients: 1) born prematurely (≤35 weeks) and ≤6 months at RSV season start; 2) with BPD requiring treatment and ≤24 months; 3) with significant CHD and ≤24 months at RSV season start.

Swedish Orphan Biovitrum AB (publ) drugs

gamifant

kepivance

kineret

orfadin

orfadin

synagis